Skip to content
Research/Metabolic Optimization/Tralesinidase Alfa

Tralesinidase Alfa

Tralesinidase alfa is an enzyme replacement therapy designed to treat metabolic disorders by supplementing deficient or malfunctioning enzymes. Its primary mechanism involves restoring normal metabolic function, which can help manage symptoms and improve quality of life in affected individuals. This compound is relevant for longevity and health optimization as it addresses underlying metabolic dysfunctions that can lead to chronic health issues.

Intelligence Profile

Research Papers

Tralesinidase Alfa has been the subject of several research studies and clinical trials, particularly focusing on its use in treating Sanfilippo Syndrome Type B (MPS IIIB). This is a condition where the body lacks a specific enzyme needed to break down complex sugar molecules, leading to severe symptoms and complications.

  1. Animal Studies:
    A study published in Toxicology Reports (2023) investigated the safety and distribution of Tralesinidase Alfa when delivered directly into the brain of juvenile cynomolgus monkeys. This approach, known as intracerebroventricular infusion, aimed to examine how the treatment distributes within the central nervous system. The study did not provide a clear sample size but highlighted the method’s potential for safe use in targeting CNS manifestations of the disease.

    Another study in The Journal of Pharmacology and Experimental Therapeutics (2022) explored the enzyme replacement therapy's efficacy in a canine model of MPS IIIB. Results showed that Tralesinidase Alfa successfully prevented the disease manifestations, suggesting its potential to modify disease progression in similar human conditions.

  2. Human Trials:
    A phase I/II clinical trial, documented in The Journal of Clinical Investigation (2023), investigated the use of intracerebroventricular Tralesinidase Alfa in patients with Sanfilippo Syndrome B. Though the paper does not specify the sample size, it discusses the initial findings regarding the treatment’s safety and potential therapeutic effects, marking an important step towards human application.

  3. Mechanism Insights:
    An earlier article from PLOS One (2019) described how BMN 250, a precursor to Tralesinidase Alfa combining lysosomal enzymes with IGF2, was absorbed by cells involved in Sanfilippo Syndrome B. This study provided essential insights into its cellular uptake mechanisms, contributing to the understanding of how this therapy might alleviate disease symptoms.

  4. Clinical Trials:
    There are ongoing clinical endeavors to further explore the therapeutic potential of Tralesinidase Alfa. For instance, a phase III trial (NCT07579910) is planned but not yet recruiting, aiming to confirm efficacy and safety in a larger population. Additionally, an early access program (NCT07733856) is currently available for patients, providing broader access to this promising treatment outside of clinical trials.

While there is promising preclinical and early clinical data supporting Tralesinidase Alfa for MPS IIIB, ongoing and future studies are crucial for confirming these findings and establishing broader therapeutic recommendations.

Disclaimer: This content is for informational purposes only and not intended as medical advice. Please consult healthcare professionals for personal medical recommendations.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.